Neumora Therapeutics Inc....
2.23
-5.91%
At close: Jan 10, 2025, 3:58 PM
2.18
-2.02%
After-hours Jan 10, 2025, 07:56 PM EST
undefined%
Bid 2.17
Market Cap 359.47M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.2
PE Ratio (ttm) -1.85
Forward PE n/a
Analyst Buy
Ask 2.2
Volume 4,526,245
Avg. Volume (20D) 2,567,009
Open 2.35
Previous Close 2.37
Day's Range 2.12 - 2.35
52-Week Range 1.83 - 21.00
Beta undefined

About NMRA

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in pa...

Industry Biotechnology
Sector Healthcare
IPO Date Sep 15, 2023
Employees 124
Stock Exchange NASDAQ
Ticker Symbol NMRA

Analyst Forecast

According to 6 analyst ratings, the average rating for NMRA stock is "Buy." The 12-month stock price forecast is $21.5, which is an increase of 866.29% from the latest price.

Buy 83.33%
Hold 16.67%
Sell 0.00%
Stock Forecasts
5 days ago · Source
+14.29%
Neumora Therapeutics shares are trading higher. B ... Unlock content with Pro Subscription
1 week ago · Source
-81.42%
Neumora Therapeutics shares are trading lower after the company announced its Phase 3 KOASTAL study did not demonstrate statistically significant improvement on its primary endpoint.